NeoGenomics, Inc. (NASDAQ:NEO) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a report issued on Friday, June 23rd.
Other research analysts also recently issued reports about the company. BTIG Research reiterated a “buy” rating and issued a $11.00 target price on shares of NeoGenomics in a research note on Sunday, May 28th. Cantor Fitzgerald set a $11.00 price target on NeoGenomics and gave the company a “buy” rating in a research note on Saturday, May 27th. Finally, Zacks Investment Research upgraded NeoGenomics from a “sell” rating to a “hold” rating in a research note on Thursday, April 27th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $10.67.
NeoGenomics (NASDAQ:NEO) opened at 9.24 on Friday. The firm has a 50-day moving average price of $7.95 and a 200-day moving average price of $8.15. NeoGenomics has a one year low of $6.90 and a one year high of $9.88. The firm’s market capitalization is $732.15 million.
NeoGenomics (NASDAQ:NEO) last announced its earnings results on Wednesday, April 26th. The medical research company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.02. NeoGenomics had a positive return on equity of 5.85% and a negative net margin of 4.92%. The company had revenue of $61.68 million for the quarter, compared to the consensus estimate of $61.26 million. During the same period last year, the business posted $0.03 EPS. The company’s revenue was up 3.3% on a year-over-year basis. Equities analysts anticipate that NeoGenomics will post $0.18 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2017/07/18/neogenomics-inc-neo-raised-to-hold-at-valuengine-updated-updated.html.
In related news, VP Jennifer Balliet sold 10,723 shares of NeoGenomics stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $8.49, for a total transaction of $91,038.27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Steven A. Ross sold 70,833 shares of NeoGenomics stock in a transaction on Monday, June 5th. The stock was sold at an average price of $7.76, for a total value of $549,664.08. Following the transaction, the insider now directly owns 4,500 shares of the company’s stock, valued at $34,920. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 84,890 shares of company stock worth $665,707. Company insiders own 12.20% of the company’s stock.
A number of institutional investors have recently modified their holdings of the company. OLD National Bancorp IN purchased a new position in shares of NeoGenomics during the second quarter valued at about $141,000. Janus Capital Management LLC purchased a new position in shares of NeoGenomics during the first quarter valued at about $13,279,000. Tudor Investment Corp ET AL boosted its position in shares of NeoGenomics by 69.8% in the first quarter. Tudor Investment Corp ET AL now owns 45,632 shares of the medical research company’s stock valued at $360,000 after buying an additional 18,762 shares in the last quarter. Highbridge Capital Management LLC purchased a new position in shares of NeoGenomics during the first quarter valued at about $531,000. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of NeoGenomics by 5.9% in the first quarter. Schwab Charles Investment Management Inc. now owns 198,419 shares of the medical research company’s stock valued at $1,566,000 after buying an additional 11,115 shares in the last quarter. 77.51% of the stock is owned by hedge funds and other institutional investors.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for NeoGenomics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.